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A B S T R A C T   
Introduction: While efficacy of deep brain stimulation for motor symptoms of neurological disorders is well 
accepted, its effects on the autonomic system remain controversial. We aimed to systematically assess all 
available evidence of deep brain stimulation effects on lower urinary tract function. 
Methods: This systematic review was performed according to the Preferred Reporting Items for Systematic Re-
views and Meta-Analyses (PRISMA) statement. Studies were identified by electronic search of Cochrane Central 
Register of Controlled Trials, Embase, Medline, Scopus, and Web of Science (last search July 12, 2019) and by 
screening of reference lists and reviews. 
Results: After screening 577 articles, we included 29 studies enrolling a total of 1293 patients. Deep brain 
stimulation of the globus pallidus internus (GPi), pedunculopontine nucleus (PPN), and subthalamic nucleus 
(STN) had an inhibitory effect on detrusor function, while deep brain stimulation of the ventral intermediate 
nucleus of the thalamus (VIM) showed an excitatory effect. In the meta-analysis, deep brain stimulation of the 
STN led to a significant increase in maximum bladder capacity (mean difference 124 mL, 95% confidence in-
terval 60–187 mL, p = 0.0001) but had no clinically relevant effects on other urodynamic parameters. Adverse 
events (reported in thirteen studies) were most commonly respiratory issues, postural instability, and dysphagia. 
Risk of bias and confounding was relatively low. 
Conclusions: Deep brain stimulation does not impair lower urinary tract function and might even have beneficial 
effects. This needs to be considered in the deep brain stimulation decision-making process helping to encourage 
and to reassure prospective patients.   
1. Introduction 
Neurogenic lower urinary tract dysfunction (NLUTD) is highly 
prevalent in patients suffering from neurological disorders, and it may 
cause storage and/or voiding symptoms [1–3]. Patient’s quality of life is 
frequently affected by NLUTD becoming one of the most challenging 
issues in the neurological patient [4]. Despite that, only few symptom-
atic treatments are currently available, including antimuscarinics, 
beta-3-adrenoceptor agonists, intradetrusor onabotulinumtoxinA in-
jections, alpha-adrenoceptor blockers, indwelling/intermittent cathe-
terization, neuromodulative and surgical procedures [4]. 
Deep brain stimulation (DBS) is a well-established and widely used 
surgical therapy for the treatment of the most common movement dis-
orders, such as Parkinson’s disease [5] and essential tremor [6]. DBS 
consists of the placement of leads in deep brain structures, i.e. different 
basal ganglia and brainstem nuclei and related tracts. DBS locally 
modulates the firing patterns of areas that are dysfunctional due to the 
ongoing pathology. Despite the widespread use of DBS, its precise 
mechanism of action remains enigmatic [7]. 
Although the main focus of DBS resides in the treatment of motor- 
associated symptoms in neurological patients [7,8], recent studies 
have suggested that patients suffering from non-motor symptoms, which 
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strongly reduce the patients’ quality of life, might also be beneficially 
influenced by this therapy [9,10]. While the efficacy of DBS for motor 
and selected non-motor (e.g. pain, sleep) symptoms is well accepted, its 
effects on the autonomic system are still controversial. 
We therefore performed a systematic review and meta-analysis to 
assess, appraise, and analyze all available evidence of the effects of DBS 
on lower urinary tract function. 
2. Methods 
2.1. Data sources and searches 
The present systematic review was performed according to the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) Statement [11]. The protocol for the review is available on 
PROSPERO (CRD42017064193) (http://www.crd.york.ac.uk 
/PROSPERO). We systematically searched Cochrane Central Register 
of Controlled Trials, Embase, Medline, Scopus, and Web of Science (from 
January 1, 1987 to July 12, 2019). No language restrictions were 
applied. We additionally searched the reference list of all included 
studies and any relevant review articles. An example of a MEDLINE 
search strategy is provided in Supplement 1. 
2.2. Study selection 
We aimed to include all original studies that reported data on the 
effects of DBS on lower urinary tract function including randomized 
controlled trials (RCTs), comparative non-RCTs, single-arm cohort 
studies, and case reports. Non-original articles and studies not published 
as full text were excluded. All identified abstracts were imported into a 
bibliography management software (EndNote X8; Thomson Reuters, 
Philadelphia, PA, USA) and sorted according to inclusion and exclusion 
folders by drag and drop. Abstracts of all identified studies were inde-
pendently reviewed by two authors (EJ and AMS), and conflicts were 
resolved by a third reviewer (TMK). Studies reporting on the effects of 
DBS (defined as any electrical stimulation of deep brain structures) on 
lower urinary tract function were reviewed in full text. 
2.3. Data extraction and risk of bias assessment 
The variables assessed included: year of publication, study type, 
number of patients, gender and age, underlying neurological disorder, 
duration of neurological disorder, stimulation site, stimulation type (i.e. 
unilateral vs. bilateral), stimulation frequencies, pulse width, stimula-
tion amplitude, DBS effects on urodynamic parameters (first desire to 
void, strong desire to void, maximum bladder capacity, maximum 
detrusor pressure, detrusor pressure during maximum flow rate, average 
flow rate, maximum flow rate, and post-void residual), and any adverse 
events. Data from eligible reports were extracted (by treatment group in 
comparative studies) in duplicate (EJ and AMS), and discrepancies were 
resolved by a third reviewer (TMK). 
Non-comparative external validity was addressed by assessing 
whether study participants were selected consecutively or were repre-
sentative of a wider patient population and whether specified con-
founding factors were reported and taken into account for analysis. The 
potential confounding factors are underlying neurological disorders (e. 
g. Parkinson’s disease (PD), essential tremor, dystonia etc.), gender, age, 
site of stimulation, and stimulation parameters. Attrition bias and se-
lective outcome reporting were also assessed (Supplement 2). This is a 
pragmatic approach informed by the methodological literature [12]. 
Finally, conflict of interest declarations, reporting of funding sources 
and role of any funding sources were investigated. 
PRISMA flow diagram
Records identified through database
searching (n=575)
Additional record identified
through additional sources (n=2)
Records after duplicates removed (n=577)
Records screened (n=577)
Full-text articles assessed for
eligibility (n=43)
Studies included in qualitative synthesis (n=29)
Studies included in quantitative synthesis: meta-analysis
(n=9)
Records excluded (n=534)
Full-text articles excluded (n=14)
Irrelevant outcomes (n=8)
Non-original articles (n=3)
































Fig. 1. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) flow diagram.  





Characteristics of included studies.  































Case report Aviles-Olmos 
[40] 
2011 1 [0/1] 71 PD 20 PPN 30 60 3 Yes AEs 





2017 123 [56/ 
67] 
59 PD [n = 82]; ET [n =
14]; dystonia [n =
18]; other [n = 9] 
NR STN; VIM; 
GPi 
NR NR NR Yes AEs 
Nazzaro [39] 2011 24 [8/16] 64 PD 10.6 STN NR NR NR Yes AEs; NMSQ; PDQ-39 
Prospective 
studies 
Dafsari [14] 2016 60 [25/35] 62 PD 10.5 STN 128 62.4 2.27–2.46 No NMSQ; NMSS; PDQ- 
8 
Dafsari [15] 2018 67 [17/50] 62 PD 10.9 STN 128 62.4 2.27–2.46 No NMSQ; NMSS; PDQ- 
8 
Dafsari [16] 2018 88 [32/56] 61 PD 10.5 STN 128 62.4 2.27–2.46 NR NMSQ; NMSS; PDQ- 
8 
Dafsari [17] 2019 101 [36/ 
65] 
62 PD 10.7 STN NR NR NR Yes NMSS; PDQ-8, AEs 
Finazzi-Agrò 
[18] 
2003 5 [2/3] 63 PD 15 STN 185 90 1.5–2.5 Yes AEs; BC; DCA; DCT; 
DPMF; MF 
Halim [19] 2011 3 [1/2] 52 PD 12.7 STN NR NR NR No BD 
Herzog [20] 2006 11 [6/5] 58 PD 15.2 STN 143.6 61.4 3.3 Yes AEs; FDV; SDV 
Herzog [21] 2008 9 [4/5] 60 PD 12.9 STN 157.8 60 3.4 No FDV; SDV 
Hwynn [22] 2011 10 [NR] 66 PD 9.9 STN [n = 9]; 
GPi [n = 1] 
NR NR NR No NMSQ; NMSS 
Kessler [23] 2008 7 [2/5] 66 ET 1.3–7.1 VIM NR NR NR No BC; Compl.; DPMF; 
FDV; IPSS; MDP; 
MF; PVR; SDV; VV 
Merola [24] 2011 19 [10/9] 62 PD 23.9 STN 130 60 3 Yes AEs 


















AEs; AUA-SI; OAB-q; 
PGI-I; QoL; SHIM 
AEs; AUA-SI; OAB-q; 
PGI-I; QoL; SHIM 
Mordasini 
[25] 
2014 11 [5/6] 48 Dystonia NR GPi NR NR NR Yes AEs; BC; DC; DPMF; 
FDV; IPSS; MDP; 
MF; PVR; SDV; VV 
Nakamura 
[26] 
2019 21 [NR] 65 PD 12.2 STN [n = 18], 
GPi [n = 3] 
NR NR NR NR Continence; PDQ-39 
Pietraszko 
[27] 
2013 19 [4/15] 59 PD 11.9 STN 130 60 1–2 No Frequency; 
hesitancy; nocturia; 
urgency [0–5 scale] 
Roy [28] 2018 5 [0/5] 63 PD 22.4 PPN 31 66 2.7 No BC; FDV 
Rukmini 
Mridula [29] 




















Seif [30] 2004 16 [9/7] 62 PD 15 STN NR NR NR No BC; DC; FDV; MDP; 
MF; PVR 
Shimizu [31] 2007 6 [2/4] 66 PD NR STN 130–185 60–120 0.5–2.6 No BC; DPMF; DCT; 
IPSS; MF; PVR 
















Yes AEs, DanPSS; IPSS 



















Wolz [34] 2012 34 [11/23] 68 PD 15.2 STN NR NR NR No Urgency 
Yamamoto 
[35] 
2018 28 [NR] 65 PD 11.8 STN [n = 22], 
GPi [n = 6] 
NR NR NR NR 
(continued on next page) 
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2.4. Data synthesis 
Studies reporting on urodynamic investigations (n = 9) with DBS ON 
and OFF state were further analyzed. Based on the sample size, mean, 
and standard deviation of the experimental group and the control group 
of the included studies, the standardized mean difference and corre-
sponding 95% confidence intervals (CI) were calculated. In cases where 
median and ranges were reported, mean and standard deviation (SD) 
were estimated with a previously described method [13]. Due to the lack 
of RCTs, we assumed that important confounding factors, i.e. different 
patients’ populations and DBS procedures, might have an impact on 
treatment effects. Thereby, a random effect model was used in the 
meta-analysis. Forest plots were generated in order to provide a visual 
representation of the results and to show the direction and magnitude of 
the effects of DBS in the most prevalent target, i.e. the subthalamic 
nucleus. Analyses and risk of bias summary and graphs were performed 
using the Cochrane RevMan software (RevMan v 5.3; Informatics and 
Knowledge Management Department; Cochrane, St Albans House, 
57–59 Haymarket, London, UK). 
2.5. Data availability 
Data are available to qualified investigators on request to the cor-
responding author. 
3. Results 
3.1. Search results 
The PRISMA flow diagram chart (Fig. 1) shows the literature search 
and results. After screening of 577 abstracts, 29 studies were included in 
the qualitative synthesis, which summarized the studies describing DBS 
effects on lower urinary tract function. Out of these 29 studies, 9 re-
ported on urodynamic parameters in DBS ON versus DBS OFF and were 
used for the quantitative analysis. Of the 29 included studies, 25 were 
prospective cohort studies [9,14–37], two were retrospective cohort 
studies [38,39], and two were case reports [40,41]. 
3.2. Study and patient characteristics 
Overall, the 29 included studies enrolled a total of 1293 patients: 429 
women (33%), 805 men (62%), and 59 patients (5%) for whom the 
gender was not reported. Patients suffered from PD (n = 1234), dystonia 
(n = 29), essential tremor (n = 21), or other neurological disorders (n =
9). Patients had leads implanted in either the globus pallidus internus 
(GPi, n = 100), pedunculopontine nucleus (PPN, n = 6), subthalamic 
nucleus (STN, n = 1004), or ventral intermediate nucleus of the thal-
amus (VIM, n = 7). In 123 patients, the lead implantation site was not 
specified but it was either the GPi, STN, or VIM. Fifty-three patients were 
in a control group without implanted DBS leads (Table 1). Studies 
included in the quantitative analysis performed sequential testing, i.e. 
first DBS ON and 10–30 min later DBS OFF state. In case of PD patients, 
anti-Parkinsonian drugs were stopped 12 h before testing. 
3.3. Efficacy of deep brain stimulation 
Treatment outcomes of DBS on lower urinary tract function are 
shown in Table 2. Urodynamic parameters are based on the total number 
of recruited patients except for 23 patients being excluded for the 
following reasons: technical issues in 1 patient [28], refusal of urody-
namic investigation in 15 patients [35], and impossibility of sponta-
neous voiding in 7 patients [30]. DBS of the GPi, PPN, and STN had an 
inhibitory effect on detrusor function, while DBS of the VIM exhibited an 
excitatory effect. In the meta-analysis (Fig. 2), DBS of the STN led to a 
significant increase in maximum bladder capacity (mean difference 124 
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relevant effects on the volume at first and strong desire to void, the 
maximum flow rate, the detrusor pressure during maximum flow rate, or 
the post-void residual. 
3.4. Safety of deep brain stimulation 
Thirteen of the 29 included studies reported adverse events (Table 1) 
possibly related to DBS procedures, and these were most commonly 
wound healing disturbance, respiratory issues, postural instability, and 
dysphagia. 
3.5. Risk of bias and confounding 
The overall risk of bias and confounding was relatively low (Sup-
plement 2a and 2b). Nevertheless, less than 50% of the studies reported 
the DBS stimulation parameters and for more than 60% of the studies 
was not clear if the participants were recruited consecutively or selec-
tively chosen. Two studies disclosed a conflict of interest [16,41] and 
one reported on the role of the funding source [16]. 
4. Discussion 
4.1. Principal findings 
Our findings indicate that DBS in the treatment of movement dis-
orders does not impair lower urinary tract function and might even have 
a beneficial impact. DBS of the GPi, PPN, or STN had an inhibitory effect 
on detrusor function (increase of bladder capacity in patients with low 
bladder capacity), while DBS of the VIM showed the opposite (decrease 
of bladder capacity in patients with high bladder capacity). The number 
of reported severe adverse events directly related to the therapy was 
very limited, demonstrating a favorable safety profile. 
4.2. Findings in the context of existing evidence 
Despite the wide use of DBS, our knowledge on its effects on auto-
nomic symptoms, especially also on the lower urinary tract function, is 
very limited. Improvements in bladder function have been observed in 
PD patients subjected to DBS of the STN. It has been hypothesized that 
the beneficial effects may be attributed to an improved integration of 
bladder afferent signals via the basal ganglia, which in turn can modu-
late the lateral frontal cortex and the anterior cingulate cortex [20,21]. 
In DBS of the GPi, PPN, and VIM, the basal ganglia, cortical, subcortical, 
and thalamic regions seem to be relevant for the impact on lower urinary 
tract function, although the mode of action remains unclear. 
4.3. Implications 
The findings of our systematic review suggest benefits and a favor-
able safety profile of DBS for treating NLUTD in patients affected by 
movement disorders via modulation of basal-ganglia-thalamo-cingulo- 
cortical pathways depending on the brain target. However, our in-
sights are limited by restricted research opportunities in humans. Ani-
mal models are therefore required to develop novel treatment options, to 
expand our knowledge, and to finally improve the quality of life of our 
patients. Indeed, DBS in animals showed relevant effects on lower uri-
nary tract function depending on the stimulation site similar to our 
findings in humans [42–44]. Thus, DBS might be used to treat storage 
and voiding dysfunction of the lower urinary tract, i.e. overactive 
bladder syndrome (by detrusor relaxation and increasing low bladder 
capacity via inhibitory DBS effects) and urinary retention (by detrusor 
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A. First desire to void
B. Strong desire to void
C. Maximum bladder capacity
D. Maximum flow rate
E. Detrusor pressure during maximum flow rate
F. Post-void residual
Fig. 2. Effects of deep brain stimulation of the subthalamic nucleus (STN) on urodynamic parameters in Parkinson’s disease patients. A) Bladder volume at first desire 
to void (mL); B) Bladder volume at strong desire to void (mL); C) Maximum bladder capacity (mL); D) Maximum flow rate (mL/s); E) Detrusor pressure during 
maximum flow rate (cmH2O); F) Post-void residual (mL). Data are shown as mean difference with 95% confidence interval. Positive values indicate an increase, 
negative values a decrease. 
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4.4. Limitations of this study 
Although we present to the best of our knowledge the first systematic 
review synthesizing all available evidence of DBS effects on lower uri-
nary tract function, there are limitations that should be addressed. 
Included papers are mostly small cohort studies with a low number of 
patients with a before-and-after treatment design, and only the study by 
Rukmini Mridula et al. [29] had a comparator. We aimed to perform 
subgroup analyses for different neurological diseases and stimulation 
sites, but 94% of the subjects suffered from PD and had DBS leads 
implanted in either the STN or, less frequently, the GPi. DBS stimulation 
parameters were not always reported, which may have an impact on our 
findings as we could not control for this potentially highly relevant co-
variate. In addition, several studies described changes in lower urinary 
tract function using a subjective scoring system not allowing for data 
pooling due to heterogenous outcomes. Two studies [43,45] investi-
gated DBS for treating NLUTD, but raw data were not available. 
Nevertheless, the overall risk of bias and confounding of the included 
studies was relatively low. 
4.5. Future directions 
Based on our findings, well-designed and powered prospective clin-
ical studies investigating DBS effects on lower urinary tract function 
using patient-reported outcomes (i.e. bladder diaries and validated 
questionnaires) as well as clinical assessment tools (i.e. free uro-
flowmetry, post-void residual measurement, and video-urodynamics) 
are highly warranted. These studies should consider and balance dif-
ferences in stimulation sites and stimulation parameters but also taking 
into account the varieties of the neurological disorders treated by DBS. 
5. Conclusions 
DBS does not impair lower urinary tract function and might even 
have beneficial effects. This is highly relevant for counselling patients in 
the informed consent procedure considering DBS and needs to be taken 
into account in the decision-making process helping to encourage and to 
reassure prospective patients. 
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A. Antonini, L. Timmermann, K. Ray Chaudhuri, EuroInf 2: Subthalamic 
stimulation, apomorphine, and levodopa infusion in Parkinson’s disease, Mov. 
Disord. 34 (3) (2019) 353–365. 
[18] E. Finazzi-Agro, A. Peppe, A. D’Amico, F. Petta, P. Mazzone, P. Stanzione, 
F. Micali, C. Caltagirone, Effects of subthalamic nucleus stimulation on urodynamic 
findings in patients with Parkinson’s disease, J. Urol. 169 (4) (2003) 1388–1391. 
[19] A. Halim, L. Baumgartner, D.K. Binder, Effect of deep brain stimulation on 
autonomic dysfunction in patients with Parkinson’s disease, J. Clin. Neurosci. 18 
(6) (2011) 804–806. 
[20] J. Herzog, P.H. Weiss, A. Assmus, B. Wefer, C. Seif, P.M. Braun, H. Herzog, 
J. Volkmann, G. Deuschl, G.R. Fink, Subthalamic stimulation modulates cortical 
control of urinary bladder in Parkinson’s disease, Brain : J. Neurol. 129 (Pt 12) 
(2006) 3366–3375. 
[21] J. Herzog, P.H. Weiss, A. Assmus, B. Wefer, C. Seif, P.M. Braun, M.O. Pinsker, 
H. Herzog, J. Volkmann, G. Deuschl, G.R. Fink, Improved sensory gating of urinary 
bladder afferents in Parkinson’s disease following subthalamic stimulation, Brain : 
J. Neurol. 131 (Pt 1) (2008) 132–145. 
[22] N. Hwynn, I. Ul Haq, I.A. Malaty, A.S. Resnick, Y. Dai, K.D. Foote, H.H. Fernandez, 
S.S. Wu, G. Oyama, C.E.t. Jacobson, S.K. Kim, M.S. Okun, Effect of Deep Brain 
Stimulation on Parkinson’s Nonmotor Symptoms Following Unilateral DBS: A Pilot 
Study, Parkinson’s Disease 2011, 2011, p. 507416. 
[23] T.M. Kessler, F.C. Burkhard, S. Z’Brun, A. Stibal, U.E. Studer, C.W. Hess, A. Kaelin- 
Lang, Effect of thalamic deep brain stimulation on lower urinary tract function, 
Eur. Urol. 53 (3) (2008) 607–612. 
[24] A. Merola, M. Zibetti, S. Angrisano, L. Rizzi, V. Ricchi, C.A. Artusi, M. Lanotte, M. 
G. Rizzone, L. Lopiano, Parkinson’s disease progression at 30 years: A study of 
subthalamic deep brain-stimulated patients, Brain : J. Neurol. 134 (Pt 7) (2011) 
2074–2084. 
E. Jörg et al.                                                                                                                                                                                                                                     
Parkinsonism and Related Disorders 79 (2020) 65–72
72
[25] L. Mordasini, T.M. Kessler, B. Kiss, M. Schupbach, C. Pollo, A. Kaelin-Lang, Bladder 
function in patients with dystonia undergoing deep brain stimulation, Park. Relat. 
Disord. 20 (9) (2014) 1015–1017. 
[26] K. Nakamura, Y. Yamanaka, Y. Higuchi, S. Hirano, R. Kuroiwa, M. Abe, A. Murata, 
Y. Iwadate, S. Kuwabara, T. Yamamoto, Improved self-perceived performance for 
continence problems in patients with Parkinson’s disease after deep brain 
stimulation, Neurology and Clinical Neuroscience 7 (2) (2019) 51–56. 
[27] W. Pietraszko, A. Furgala, A. Gorecka-Mazur, P. Thor, M. Moskala, J. Polak, A. 
D. Surowka, A. Krygowska-Wajs, Efficacy of deep brain stimulation of the 
subthalamic nucleus on autonomic dysfunction in patients with Parkinson’s 
disease, Folia Med. Cracov. 53 (2) (2013) 15–22. 
[28] H.A. Roy, D. Pond, C. Roy, B. Forrow, T. Foltynie, L. Zrinzo, H. Akram, T.Z. Aziz, J. 
J. FitzGerald, A.L. Green, Effects of pedunculopontine nucleus stimulation on 
human bladder function, Neurourol. Urodyn. 37 (2) (2018) 726–734. 
[29] K. Rukmini Mridula, R. Borgohain, S.A. Jabeen, G. Padmaja, V.S. Bandaru, 
P. Ankathi, M.A. Kanikannan, M.S. Ali Khan, Comparison of frequencies of non 
motor symptoms in Indian Parkinson’s disease patients on medical management 
versus deep brain stimulation: a case-control study, Iranian journal of neurology 14 
(2) (2015) 86–93. 
[30] C. Seif, J. Herzog, C. van der Horst, B. Schrader, J. Volkmann, G. Deuschl, K. 
P. Juenemann, P.M. Braun, Effect of subthalamic deep brain stimulation on the 
function of the urinary bladder, Ann. Neurol. 55 (1) (2004) 118–120. 
[31] N. Shimizu, S. Matsumoto, Y. Mori, N. Yoshioka, H. Uemura, N. Nakano, 
M. Taneda, [Effects of deep brain stimulation on urodynamic findings in patients 
with Parkinson’s disease], Hinyokika kiyo, Acta Urol. Jpn. 53 (9) (2007) 609–612. 
[32] K. Winge, K.K. Nielsen, Bladder dysfunction in advanced Parkinson’s disease, 
Neurourology and urodynamics 31 (8) (2012) 1279–1283. 
[33] L.P. Witte, V.J.J. Odekerken, J.A. Boel, P.R. Schuurman, L.C. Gerbrandy- 
Schreuders, R.M.A. de Bie, Does deep brain stimulation improve lower urinary 
tract symptoms in Parkinson’s disease? Neurourol. Urodyn. 37 (1) (2017) 354–359. 
[34] M. Wolz, J. Hauschild, J. Koy, M. Fauser, L. Klingelhofer, G. Schackert, 
H. Reichmann, A. Storch, Immediate effects of deep brain stimulation of the 
subthalamic nucleus on nonmotor symptoms in Parkinson’s disease, Park. Relat. 
Disord. 18 (8) (2012) 994–997. 
[35] T. Yamamoto, T. Uchiyama, M. Asahina, Y. Yamanaka, S. Hirano, Y. Higuchi, 
S. Kuwabara, Urinary symptoms are correlated with quality of life after deep brain 
stimulation in Parkinson’s disease, Brain Behav 8 (12) (2018), e01164. 
[36] M. Zibetti, E. Torre, A. Cinquepalmi, M. Rosso, A. Ducati, B. Bergamasco, 
M. Lanotte, L. Lopiano, Motor and nonmotor symptom follow-up in parkinsonian 
patients after deep brain stimulation of the subthalamic nucleus, Eur. Neurol. 58 
(4) (2007) 218–223. 
[37] H. Zong, F. Meng, Y. Zhang, G. Wei, H. Zhao, Clinical study of the effects of deep 
brain stimulation on urinary dysfunctions in patients with Parkinson’s disease, 
Clin. Interv. Aging 14 (2019) 1159–1166. 
[38] C. Buhmann, T. Huckhagel, K. Engel, A. Gulberti, U. Hidding, M. Poetter-Nerger, 
I. Goerendt, P. Ludewig, H. Braass, C.U. Choe, K. Krajewski, C. Oehlwein, 
K. Mittmann, A.K. Engel, C. Gerloff, M. Westphal, J.A. Koppen, C.K.E. Moll, 
W. Hamel, Adverse events in deep brain stimulation: A retrospective long-term 
analysis of neurological, psychiatric and other occurrences, PloS One 12 (7) 
(2017), e0178984. 
[39] J.M. Nazzaro, R. Pahwa, K.E. Lyons, The impact of bilateral subthalamic 
stimulation on non-motor symptoms of Parkinson’s disease, Park. Relat. Disord. 17 
(8) (2011) 606–609. 
[40] I. Aviles-Olmos, T. Foltynie, J. Panicker, D. Cowie, P. Limousin, M. Hariz, C. 
J. Fowler, L. Zrinzo, Urinary incontinence following deep brain stimulation of the 
pedunculopontine nucleus, Acta Neurochir. 153 (12) (2011) 2357–2360. 
[41] F.T. Liu, L.Q. Lang, R.Y. Zhou, R. Feng, J. Hu, J. Wang, J.J. Wu, Urinary 
incontinence following deep brain stimulation of the globus pallidus internus: Case 
report, J. Neurosurg. (2019) 1–3. 
[42] S.C. Chen, P.Y. Chu, T.H. Hsieh, Y.T. Li, C.W. Peng, Feasibility of deep brain 
stimulation for controlling the lower urinary tract functions: An animal study, Clin. 
Neurophysiol. 128 (12) (2017) 2438–2449. 
[43] A.L. Green, E. Stone, H. Sitsapesan, B.W. Turney, J.H. Coote, T.Z. Aziz, J.A. Hyam, 
T.A. Lovick, Switching off micturition using deep brain stimulation at midbrain 
sites, Ann. Neurol. 72 (1) (2012) 144–147. 
[44] E. Stone, J.H. Coote, T.A. Lovick, Effect of electrical vs. chemical deep brain 
stimulation at midbrain sites on micturition in anaesthetized rats, Acta Physiol. 
214 (1) (2015) 135–145. 
[45] K. Winge, K.K. Nielsen, H. Stimpel, A. Lokkegaard, S.R. Jensen, L. Werdelin, Lower 
urinary tract symptoms and bladder control in advanced Parkinson’s disease: 
Effects of deep brain stimulation in the subthalamic nucleus, Movement disorders. 
22 (2) (2007) 220–225. 
E. Jörg et al.                                                                                                                                                                                                                                     
